ReviewCardio-oncology (London, England)2025
Impact of advanced lung cancer inflammation index on all-cause mortality among patients with heart failure: a systematic review and meta-analysis with reconstructed time-to-event data.
Review in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Advanced lung cancer inflammation index and mortality risk in patients with cardiovascular disease.BMC cardiovascular disorders · 2026Article
- Risk stratification of postoperative enteral feeding intolerance using explainable machine learning in oral cancer free flap reconstruction.Frontiers in nutrition · 2026Article
- Association of the advanced lung cancer inflammation index and controlling nutritional status score with atrial fibrillation in COPD patients: a multicenter cross-sectional study.Frontiers in nutrition · 2026Article
- The role of oxidative balance score in Cardiovascular-Kidney-Metabolic syndrome progression and mortality: insights from NHANES 1999-2020.Frontiers in nutrition · 2025Article
- Association between inflammation- and nutrition-related indicators and mortality in patients with heart failure: a cohort study.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is associated with systemic inflammation and hypercatabolic syndrome, impacting body metabolism. The advanced lung cancer inflammation index (ALI) is a novel inflammatory and nutritional biomarker. We aimed to investigate the prognostic role of ALI in patients with HF.
methodsWe comprehensively searched PubMed, WOS, SCOPUS, EMBASE, and CENTRAL through October 2024. We conducted a pair-wise and prognostic systematic review and meta-analysis with a reconstructed time-to-event data meta-analysis. All analyses were performed using R V. 4.3.1. This meta-analysis was registered at PROSPERO (CRD42024535227).
resultsWe included five studies with 2,795 patients. In the pair-wise meta-analysis, ALI ≤ 25 was significantly associated with an increased incidence of all-cause mortality compared with ALI > 25 (risk ratio [RR] 1.73, 95% confidence interval [CI] 1.36-2.21, P < 0.01). On the adjusted prognostic meta-analysis, higher ALI was significantly associated with a reduction in the risk of all-cause mortality (hazards ratio [HR] 0.45, 95% CI 0.35-0.58-, P < 0.01). The reconstructed Kaplan Meier showed that ALI > 25 was significantly associated with a 56% reduction in the risk of all-cause mortality compared with ALI ≤ 25 (HR 0.44, 95% CI 0.38-0.50, P < 0.000001).
conclusionAmong patients with HF, a low ALI was associated with a higher incidence of all-cause mortality rate than those with a high ALI. These findings suggest that ALI can be used for prognostic stratification and aid clinical decision-making in HF management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.